Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Assessment of Antithrombin III, Protein C, Protein S, and D-dimer Levels in Acute Leukemia Patients
研究概览
简要总结
The goal of this observational study is to evaluate the levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients with Acute Leukemia (Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)). The main questions it aims to answer are:
What are the levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients with Acute Lymphoblastic Leukemia? What are the levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients with Acute Myeloid Leukemia? Researchers will compare patients with Acute Leukemia (30 with ALL and 30 with AML) to 30 healthy control subjects to see if there are significant differences in the levels of Antithrombin III, Protein C, Protein S, and D-dimer.
Participants will:
Undergo full history and clinical examination. Have routine hematological analysis including Complete Blood Count (CBC), blood film, Erythrocyte sedimentation rate (ESR), Prothrombin Time Test and INR (PT/INR), and partial thromboplastin time (PTT).
Have specific tests for quantitative measurement of Antithrombin III, Protein C, Protein S, and D-dimer.
Undergo Flow cytometry immunophenotyping.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •patients with leukemia in group 1 and
- •willing to participate in the study.
排除标准
- •refusing to participate.
- •patients with know to have either hereditary thrombophilia or current thrombosis.
研究组 & 干预措施
acute lymphoblastic leukemia
patients diagnosed with acute lymphoblastic leukemia.
干预措施: Antithrombin III (Diagnostic Test)
acute lymphoblastic leukemia
patients diagnosed with acute lymphoblastic leukemia.
干预措施: Protein C (Diagnostic Test)
acute lymphoblastic leukemia
patients diagnosed with acute lymphoblastic leukemia.
干预措施: Protein S (Diagnostic Test)
acute lymphoblastic leukemia
patients diagnosed with acute lymphoblastic leukemia.
干预措施: D-dimer (Diagnostic Test)
acute lymphoblastic leukemia
patients diagnosed with acute lymphoblastic leukemia.
干预措施: Flow cytometry immunophenotyping (Diagnostic Test)
acute myeloid leukemia
patients diagnosed with acute myeloid leukemia.
干预措施: Antithrombin III (Diagnostic Test)
acute myeloid leukemia
patients diagnosed with acute myeloid leukemia.
干预措施: Protein C (Diagnostic Test)
acute myeloid leukemia
patients diagnosed with acute myeloid leukemia.
干预措施: Protein S (Diagnostic Test)
acute myeloid leukemia
patients diagnosed with acute myeloid leukemia.
干预措施: D-dimer (Diagnostic Test)
acute myeloid leukemia
patients diagnosed with acute myeloid leukemia.
干预措施: Flow cytometry immunophenotyping (Diagnostic Test)
control group
controlled group include healthy persons not suffering from acute leukemia either clinically or laboratory
干预措施: Antithrombin III (Diagnostic Test)
control group
controlled group include healthy persons not suffering from acute leukemia either clinically or laboratory
干预措施: Protein C (Diagnostic Test)
control group
controlled group include healthy persons not suffering from acute leukemia either clinically or laboratory
干预措施: Protein S (Diagnostic Test)
control group
controlled group include healthy persons not suffering from acute leukemia either clinically or laboratory
干预措施: D-dimer (Diagnostic Test)
control group
controlled group include healthy persons not suffering from acute leukemia either clinically or laboratory
干预措施: Flow cytometry immunophenotyping (Diagnostic Test)
结局指标
主要结局
Assessment of Antithrombin III, Protein C, Protein S, and D-dimer Levels in Acute Leukemia Patients
时间窗: at the time of patient recruitment for the study.
To evaluate and compare the quantitative levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients diagnosed with Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) against healthy control subjects. This assessment will help determine any significant differences in these coagulation parameters within the different acute leukemia subtypes and in comparison to healthy individuals.
次要结局
未报告次要终点
研究者
Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy
lecturer and consultant at Obstetrics and Gynecology Department.
Al-Azhar University